and transplant hepatology by the American Board of Internal Medicine and joined the UT Southwestern faculty in 2010. His research focuses on monitoring liver cirrhosis patients, in particular for diagnosing and treating liver cancer before it...
hubs for global beauty consumers. In addition, MEDIPEEL has entered Namsi Pharmacy, a heritage pharmacy established in 1954 and operated across three generations, further strengthening its presence within Korea's trusted K-Pharmacy network. The...
with neurological conditions. The company advances work originally developed by iota Biosciences, which was founded in 2017 to pioneer cutting‑edge bioelectronic technologies and is now powered by Astellas. Epia Neuro’s platform integrates...
molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1). Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective...
13th International Conference on Chemical and Biological Sciences (ICCBS 2026) will be held in Osaka, Japan during, co-sponsored by Network Joint Research Center for Materials and Devices: Dynamic Alliance for Open Innovation Bridging Human,...
Tiger BioSciences announced the launch of carePAC™, a line of pre-configured wound care convenience kits designed to simplify dressing changes and improve access to essential wound care supplies for patients managing wounds at home. carePAC™ kits...
fed-batch cultures, establishing stable pools in as little as four weeks, and supporting selection of stable clones within 14 weeks, helping to streamline progression from early development to commercial manufacturing. “Biologics developers face...
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of its Biologics License...
as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating inobrodib 20 mg in combination with standard doses of pomalidomide (pom) and...
for the life sciences industry, delivering end-to-end support across the entire product lifecycle. With a presence in 150+ countries, operations in 50+ countries, and a team of over 2,000 professionals, PLG supports pharmaceutical, biotechnology,...
track record in securing access for, and launching, innovative medicines as well as driving commercial operations of up to €150m in revenue. Constance joins Avanzanite with more than two decades of experience across global biopharmaceutical...
for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing its total funding in equity and grants to $42 million. Investors...
also strongly condemned management’s compliance failures. Despite a Labor-Management Win-Win Agreement signed on December 1 to resolve a broad array of legal disputes—including aggravated trespassing, violations of the Public Interest Whistleblower...
drug development, and commercial leadership to Convergent, as the Company completes its Phase 2 study of CONV01-α, a prostate specific membrane antigen (PSMA)-targeted Actinium-225 (Ac-225) radioantibody in patients with metastatic...
work synergistically to prime and activate the immune system to eradicate myeloma cells that express the BCMA protein.1 This approval offers a potential new standard of care (SOC) as early as second line and brings a novel treatment approach for...
evidence supporting product safety, performance, and patient outcomes across global markets. Calaway brings more than 17 years of experience in clinical operations, evidence generation strategy, and regulatory-aligned research programs within the...
neuroprotective therapies in neurodegenerative diseases, today announced the final close of its oversubscribed $105 million Series C funding. The round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation...
between ages five weeks to five months and continues for approximately six months. It is estimated that approximately 5,000-10,000 infants are treated with HEMANGEOL annually in the United States. The transaction is expected to be accretive to 2026...
is contractual. US-Rx Care provides employers with a conflict-free model that eliminates pharmacy ownership, operates on a 100 percent pass-through basis for discounts and rebates, and charges a transparent administrative fee. This structure offers...
of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral hypoxia-inducible factor-2...
